Cargando…

COVID-19 in a temporal relation to the onset of multiple sclerosis

Neurological complications of COVID-19 have been described. We present the case of a 27-year-old woman who developed COVID-19 in April 2020. She continued to present anosmia and ageusia eight months later. Six months after contracting COVID-19, she developed dysesthesia, hypoesthesia and hyperreflex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fragoso, Yara D., Pacheco, Filippe A.S., Silveira, Guilherme L., Oliveira, Rodrigo A., Carvalho, Vitor M., Martimbianco, Ana Luiza C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902206/ https://www.ncbi.nlm.nih.gov/pubmed/33662859 http://dx.doi.org/10.1016/j.msard.2021.102863

Ejemplares similares

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis
por: Kashoo, Faizan Z., et al.
Publicado: (2020)

Early and severe cognitive impairment in multiple sclerosis
por: Mendes, Maria Fernanda, et al.
Publicado: (2012)

A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
por: Santos, Giovanna Marcílio, et al.
Publicado: (2021)

Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab
por: Guevara, Carlos, et al.
Publicado: (2020)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2022)

Characteristics of COVID-19 disease in multiple sclerosis patients
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Andréasson, Kristofer, et al.
Publicado: (2021)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
por: Simpson-Yap, Steve, et al.
Publicado: (2022)

The COVID-19 pandemic and a reflection on the conduct of clinical trials in times of war
por: Pacheco, Rafael Leite, et al.
Publicado: (2021)

What is an “ongoing” clinical trial? An analysis of different sources revealed heterogeneous definitions of when a clinical trial starts and ends: a meta-research study
por: Pacheco, Rafael Leite, et al.
Publicado: (2023)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020)

The lateralization of clinical findings might not affect the clinical outcome in multiple sclerosis
Publicado: (2020)

Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era
por: Nicholas, Jacqueline A., et al.
Publicado: (2021)

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
por: Aguirre, Clara, et al.
Publicado: (2020)

COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak
por: Buonomo, Antonio, et al.
Publicado: (2020)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina
por: Cristiano, E, et al.
Publicado: (2020)

Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada
por: Solomon, Jacqueline M., et al.
Publicado: (2022)

The unexpected finding of a hemangioblastoma on the cerebellum of a patient undergoing treatment with natalizumab for multiple sclerosis
por: Fragoso, Yara Dadalti, et al.
Publicado: (2017)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

The big challenge for neurologists in treating patients with multiple sclerosis in the post-COVID-19 era
por: Naser Moghadasi, Abdorreza
Publicado: (2020)

Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Zamanian, Roham T., et al.
Publicado: (2021)

Effect of 12 weeks of aquatic strength training on individuals with multiple sclerosis
por: SCORCINE, Claudio, et al.
Publicado: (2022)

What to do when the choice is no choice at all? A critical view on nutritional recommendations for CoVID-19 quarantine
por: Ribeiro, Andre Luis Ribeiro, et al.
Publicado: (2020)

Age of Onset in Concordant Twins and Other Relative Pairs With Multiple Sclerosis
por: Sadovnick, A. Dessa, et al.
Publicado: (2009)

Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
por: Jack, Dominic, et al.
Publicado: (2020)

Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod
por: Mallucci, Giulia, et al.
Publicado: (2020)

COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
por: Luetic, Geraldine, et al.
Publicado: (2021)

Adult onset xanthogranuloma associated with IgG4-related disease
por: Leung, Kai Ching Peter, et al.
Publicado: (2018)

Differential diagnosis of multiple sclerosis in Latin America
por: Fragoso, YD, et al.
Publicado: (2017)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Osteochondritis dissecans of the trochlea: case report()
por: Gracitelli, Guilherme Conforto, et al.
Publicado: (2018)

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
por: De Angelis, Marcello, et al.
Publicado: (2020)

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
por: Gelibter, Stefano, et al.
Publicado: (2021)

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022)

Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications
por: Levit, Elle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hkvhleo68md2ieikug72stordi